eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest
News
Daily treatment with a low dose of eRapa, Emtora Biosciences‘ new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led to immune system cell boosting in ... Read more